Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of ASC16 (Ravidasvir) in Healthy Volunteers
NCT03430830Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jan 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ravidasvir in hepatitis C (HCV) (6 arms), sponsored by Ascletis Pharma Inc. Primary endpoints: Peak Plasma Concentration at 27 days and Area Under the Curve at 27 days. Started Jan 2018; status: completed.
02
Drugs
ravidasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03430830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430830.